GSK3B and neoplasm: Taken together, we speculate that E-cadherin, Slug and GSK3β could be exploited as markers and pharmacologic or antibody-based therapies targeting the Wnt pathway components, which may not only improve the management of breast cancer, but also affect tumor recurrence and/or metastasis.